450 related articles for article (PubMed ID: 18817633)
41. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
42. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
Neamati N; Hong H; Mazumder A; Wang S; Sunder S; Nicklaus MC; Milne GW; Proksa B; Pommier Y
J Med Chem; 1997 Mar; 40(6):942-51. PubMed ID: 9083483
[TBL] [Abstract][Full Text] [Related]
43. Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays.
Hu G; Li X; Zhang X; Li Y; Ma L; Yang LM; Liu G; Li W; Huang J; Shen X; Hu L; Zheng YT; Tang Y
J Med Chem; 2012 Nov; 55(22):10108-17. PubMed ID: 23046280
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles.
Middleton T; Lim HB; Montgomery D; Rockway T; Tang H; Cheng X; Lu L; Mo H; Kohlbrenner WE; Molla A; Kati WM
Antiviral Res; 2004 Oct; 64(1):35-45. PubMed ID: 15451177
[TBL] [Abstract][Full Text] [Related]
45. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Clement O; Shoemaker R; Sei S; Neamati N
J Med Chem; 2005 Jan; 48(1):111-20. PubMed ID: 15634005
[TBL] [Abstract][Full Text] [Related]
46. Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors.
Sechi M; Derudas M; Dallocchio R; Dessì A; Bacchi A; Sannia L; Carta F; Palomba M; Ragab O; Chan C; Shoemaker R; Sei S; Dayam R; Neamati N
J Med Chem; 2004 Oct; 47(21):5298-310. PubMed ID: 15456274
[TBL] [Abstract][Full Text] [Related]
47. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro.
Deprez E; Barbe S; Kolaski M; Leh H; Zouhiri F; Auclair C; Brochon JC; Le Bret M; Mouscadet JF
Mol Pharmacol; 2004 Jan; 65(1):85-98. PubMed ID: 14722240
[TBL] [Abstract][Full Text] [Related]
48. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
Gupta P; Kumar R; Garg P; Singh IP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
[TBL] [Abstract][Full Text] [Related]
49. 1,4-Bis(5-(naphthalen-1-yl)thiophen-2-yl)naphthalene, a small molecule, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular Lens epithelium-derived growth factor.
Gu WG; Ip DT; Liu SJ; Chan JH; Wang Y; Zhang X; Zheng YT; Wan DC
Chem Biol Interact; 2014 Apr; 213():21-7. PubMed ID: 24480521
[TBL] [Abstract][Full Text] [Related]
50. Rational design of novel diketoacid-containing ferrocene inhibitors of HIV-1 integrase.
da Silva CH; Del Ponte G; Neto AF; Taft CA
Bioorg Chem; 2005 Aug; 33(4):274-84. PubMed ID: 16023487
[TBL] [Abstract][Full Text] [Related]
51. A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
De Luca L; Barreca ML; Ferro S; Iraci N; Michiels M; Christ F; Debyser Z; Witvrouw M; Chimirri A
Bioorg Med Chem Lett; 2008 May; 18(9):2891-5. PubMed ID: 18417342
[TBL] [Abstract][Full Text] [Related]
52. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J
J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974
[TBL] [Abstract][Full Text] [Related]
53. HIV-1 integrase inhibitors: 2005-2006 update.
Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
[TBL] [Abstract][Full Text] [Related]
54. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
Wang Z; Bennett EM; Wilson DJ; Salomon C; Vince R
J Med Chem; 2007 Jul; 50(15):3416-9. PubMed ID: 17608468
[TBL] [Abstract][Full Text] [Related]
55. Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
Sriram D; Yogeeswari P; Senchani G; Banerjee D
Bioorg Med Chem Lett; 2007 Apr; 17(8):2372-5. PubMed ID: 17376679
[TBL] [Abstract][Full Text] [Related]
56. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore.
Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH
Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781
[TBL] [Abstract][Full Text] [Related]
57. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors.
Tramontano E; Onidi L; Esposito F; Badas R; La Colla P
Biochem Pharmacol; 2004 May; 67(9):1751-61. PubMed ID: 15081874
[TBL] [Abstract][Full Text] [Related]
58. Active site binding modes of curcumin in HIV-1 protease and integrase.
Vajragupta O; Boonchoong P; Morris GM; Olson AJ
Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and anti-integrase activity of catechol-DKA hybrids.
Maurin C; Bailly F; Mbemba G; Mouscadet JF; Cotelle P
Bioorg Med Chem; 2006 May; 14(9):2978-84. PubMed ID: 16412645
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.
Zawahir Z; Neamati N
Bioorg Med Chem Lett; 2006 Oct; 16(19):5199-202. PubMed ID: 16879966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
